The Urgent Need for Breakthrough Therapies and a World Without Type 1 Diabetes.

Diabetes Ther

Breakthrough T1D, 200 Vesey Street, 28th Floor, New York, NY, 10281, USA.

Published: June 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Despite significant progress, type 1 diabetes (T1D) still results in premature death, significant complications, and a substantial daily burden for those affected. T1D remains a lifelong condition that demands constant vigilance and resilience and has a significant social and economic impact. Individuals with T1D must walk a tightrope to minimize disease-related complications that result from insufficient insulin while also avoiding adverse effects from too much insulin. Achieving this balance is challenging, as diet, activity, medications, physiology, the environment, stress, and many other aspects of daily living all affect glucose levels, often differently from day to day. Persistent challenges of T1D go beyond maintaining glycemic control and include managing long-term complications and preventing potentially life-threating adverse reactions from insulin therapy, and the emotional and cognitive burdens that often lead to diabetes distress and burnout. The T1D community-researchers, sponsors, clinicians, those living with T1D, and advocates-must look beyond managing symptoms of T1D and aim for better treatments and to bring cures. Emerging therapies need clear and efficient regulatory pathways, and new solutions are needed to address ongoing regulatory challenges. The perspectives of people with T1D must be front and center in research and regulatory decision-making. Through the collective efforts of the T1D community, the urgent needs of those with T1D can be met, and T1D can be made a thing of the past.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085400PMC
http://dx.doi.org/10.1007/s13300-025-01735-6DOI Listing

Publication Analysis

Top Keywords

t1d
11
type diabetes
8
urgent breakthrough
4
breakthrough therapies
4
therapies type
4
diabetes despite
4
despite progress
4
progress type
4
diabetes t1d
4
t1d premature
4

Similar Publications

Deciphering disease-specific glycosylation: unraveling diabetes subtypes through serum glycopattern.

Anal Bioanal Chem

September 2025

Center for Clinical Mass Spectrometry, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, Jiangsu, China.

Latent autoimmune diabetes in adults (LADA) is a slowly progressing form of diabetes that develops in adulthood, characterized by autoimmune destruction of pancreatic β-cells and subsequent insulin deficiency, akin to type 1 diabetes (T1D). Due to its shared genetic, immunological, and metabolic features with both T1D and type 2 diabetes (T2D), LADA is frequently misdiagnosed and inappropriately treated as T2D. To address this, we developed the A.

View Article and Find Full Text PDF

Predicting stimulated C-peptide in type 1 diabetes using machine learning: a web-based tool from the T1D exchange registry.

Diabetes Res Clin Pract

September 2025

Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey.

Aims: The mixed-meal tolerance test (MMTT), though considered the gold standard for evaluating residual beta-cell function in type 1 diabetes mellitus (T1D), is impractical for routine use. We aimed to develop and validate a machine learning (ML) model to predict MMTT-stimulated C-peptide categories using routine clinical data.

Methods: Data from 319 individuals in the T1D Exchange Registry with complete MMTT and clinical information were analyzed.

View Article and Find Full Text PDF

Although genomic sequencing presents groundbreaking newborn screening (NBS) opportunities, critical feasibility and utility questions remain. Here we present initial results from the Early Check program-an observational study assessing the feasibility and clinical utility of genomic NBS in North Carolina. Recruitment was statewide through mailed letters with electronic consent.

View Article and Find Full Text PDF

TLR5 influences the development of type 1 diabetes.

BMJ Open Diabetes Res Care

September 2025

Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg Campus, Frederiksberg, Denmark.

Unlabelled: In mammalian and human life, it is important that the immune system defends against microorganisms. Although there is a huge overlap, innate cells are good against bacteria, whereas T cells are good against viruses, mainly because of antibody production via T helper and B lymphocytes. Toll-like receptor 5 (TLR5) is a regulator; when it is highly expressed, T cells are inhibited, and innate cells are favored.

View Article and Find Full Text PDF

Finerenone in type 1 diabetes and chronic kidney disease: short-term efficacy and safety insights.

Int Urol Nephrol

September 2025

National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Xuanwu District, No. 305 East Zhongshan Road, Nanjing, 210016, Jiangsu, China.

Purpose: To evaluate the short-term efficacy and safety of finerenone in patients with type 1 diabetes (T1D) and chronic kidney disease (CKD).

Methods: A retrospective cohort study was conducted on a relatively small sample of 23 patients diagnosed with T1D and CKD between January 2023 and August 2024. All patients received renin-angiotensin system inhibitors (RASi), with 12 patients additionally treated with finerenone.

View Article and Find Full Text PDF